Skip to content
GERICLINICS

Flashcards · Module 43

🦴 Second-Line Bone Anabolics & Advanced Osteoporosis

4 of 4 cards published · read by the site’s author on 22 November 2026

Teriparatide & Abaloparatide: Building bone from scratch

Needs clinical review

Anti-Resorptive vs. Anabolic Agents:

  • Bisphosphonates & Denosumab: Are "Anti-Resorptive" — they mainly inhibit osteoclastic bone resorption, with only later, secondary effects on bone formation.

  • Teriparatide (Forteo - recombinant human PTH 1-34) and Abaloparatide (Tymlos - PTHrP analog): Are ANABOLIC AGENTS — they stimulate osteoblasts to actively build new trabecular and cortical bone!

How Intermittent PTH Builds Bone:

  • Given intermittently (once-daily subcutaneous injections), teriparatide is anabolic, with effects most marked in trabecular bone.

Indications:

  • Very high fracture risk (UK guidance): a recent vertebral fracture (within 2 years), 2 or more vertebral fractures, or a T-score of −3.5 or lower

  • Second line when bisphosphonates are not tolerated

Dosing & Limits:

  • Daily subcutaneous injection (teriparatide 20 µg).

  • Duration: limited to 24 months, as a once-only course.

  • 🚨 The Sequence Rule: When the anabolic course ends (teriparatide 24 months), start alendronate, zoledronate or denosumab without delay!

One-Liner: Teriparatide and abaloparatide are daily injections that build new bone in very-high-risk osteoporosis; when the course ends (teriparatide 24 months), start an antiresorptive without delay.
Sources checked (3) · 21 November 2026

Note: In a trial of one year of parathyroid hormone, the bone density gained was kept with alendronate but lost when no antiresorptive followed. (One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis (2005))

Romosozumab (Evenity): The dual-action sclerostin inhibitor

Needs clinical review

The Molecular Secret of Sclerostin:

Sclerostin is a regulatory factor in bone metabolism: blocking it increases bone formation.

How Romosozumab Works:

Romosozumab is a monoclonal antibody that binds and inhibits Sclerostin!

  • 🟢 Stimulates bone formation.

  • 🔴 Inhibits bone resorption.

  • Unlike most osteoporosis drugs, which are either anabolic or antiresorptive, it has a DUAL ACTION!

The Regimen:

  • Two subcutaneous injections once monthly for exactly 12 months.

  • Large, rapid rise in spine bone density (+11.3% in 1 year at 210 mg monthly, against 4.1% with alendronate and 7.1% with teriparatide, in a phase 2 trial).

🚨 The FDA Black-Box Cardiovascular Warning (THE BOARD TRAP!):

Romosozumab carries a black-box warning: it may increase the risk of myocardial infarction, stroke, and cardiovascular death!

  • Contraindication (US label): Do NOT start Romosozumab in a patient who has had a myocardial infarction or stroke within the past year!

One-Liner: Romosozumab inhibits sclerostin, building bone and reducing resorption over a single 12-month course; do not use it after a heart attack or stroke (US label: within the past year; UK guidance: ever).
Sources checked (4) · 21 November 2026

Note: In the US label, bone formation rises more than resorption falls. (DailyMed - EVENITY- romosozumab-aqqg injection, solution)

Note: UK guidance goes further: any history of myocardial infarction or stroke is a contraindication. (UK clinical guideline for the prevention and treatment of osteoporosis (2022))

Vertebroplasty vs. Kyphoplasty in Vertebral Compression Fractures

Needs clinical review

The Agony of a Collapsed Vertebra:

An 80-year-old with severe osteoporosis coughs and feels a sudden, excruciating, sharp thoracic back pain. X-ray confirms an acute L1 vertebral compression fracture.

The Two Minimally Invasive Procedures:

  1. Vertebroplasty: Percutaneous injection of medical-grade bone cement into the fractured vertebra, under light sedation or general anaesthesia; the cement hardens into an internal cast.

  2. Kyphoplasty: Similar, but an inflatable balloon is first expanded in the fractured vertebra, and then cement is injected.

The Great Clinical Controversy:

  • Sham-controlled trials (such as the landmark Buchbinder trials) showed that routine vertebroplasty had no significant benefit over a sham procedure for typical subacute fractures.

  • Does early treatment help? In the Cochrane review the effect did not differ by duration of pain (acute vs subacute).

    • Serious adverse events include osteomyelitis, cord compression, thecal sac injury and respiratory failure.

One-Liner: Vertebroplasty and kyphoplasty inject bone cement into fractured vertebrae; sham-controlled trials show no important benefit, and guidelines do not support their routine use.
Sources checked (4) · 21 November 2026

Vitamin D Dosing, Toxicity & Hypercalcemia: Avoiding annual mega-doses

Needs clinical review

The Essential Vitamin:

Vitamin D (25-OH-D) and calcium are key to skeletal health.

Diagnostic Targets:

  • Adequate: at least 20 ng/mL (50 nmol/L) meets the needs of 97.5% of people (IOM).

  • Higher is not better: higher levels were not consistently linked with more benefit, and some outcomes had risks at both low and high levels.

The Replenishment Protocol:

  • If deficient: a loading dose of 100,000 to 300,000 IU orally, in divided doses, followed by daily maintenance.

  • Daily Maintenance Dose: 800 up to 2,000 IU daily of vitamin D in osteoporosis, with calcium of at least 700 mg daily, preferably from the diet.

The Dangerous Mega-Dose Trap (The Board Question!):

Some clinicians gave patients a single, massive annual dose of 500,000 IU of Vitamin D once a year to improve compliance.

  • 🚨 THE DISASTER: In a randomised trial, the annual mega-dose increased falls by 31% (in the first 3 months) and fractures by 26%!

  • Rule: routine large intermittent doses of vitamin D (e.g. 60,000 IU or more) are not advised: they were linked with more falls and fractures.

One-Liner: Correct vitamin D deficiency with a divided loading dose (100,000–300,000 IU), then 800–2,000 IU daily; avoid large intermittent doses (60,000 IU or more), such as the annual 500,000 IU dose that increased falls and fractures.
Sources checked (3) · 21 November 2026